UBS analyst Michael Yee reiterated a Neutral rating and $150.00 price target on Moderna (NASDAQ: MRNA).The analyst commented, "The highly ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments